Sequencing of treatments for advanced/metastatic kidney cancer
During the American Society of Clinical Oncology Annual Meeting earlier [...]
Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?
At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
EIKCS 2022: Debate about later-line treatments
At the 2022 European International Kidney Cancer Symposium (EIKCS) in [...]
EIKCS 2022: Which is the best combination therapy?
During 2022 European International Kidney Cancer Symposium (EIKCS) in Antwerp, [...]
ASCO GU 2022: Choosing between combination treatments for advanced kidney cancer
Combination therapies have revolutionised the first-line treatment of metastatic clear [...]
Outcomes and side effects after first-line treatment with combination therapies for kidney cancer
This report looked at the results from 4 studies comparing [...]
Stereotactic radiotherapy for metastatic kidney cancer patients on TKIs
This phase 2 study looked at the use of stereotactic [...]
ESMO 2021: TKI treatment breaks for advanced/metastatic kidney cancer – the STAR study
There is increasing interest in using treatment breaks to reduce [...]
Age-based outcomes in kidney cancer patients treated with first-line targeted therapy or immunotherapy
This study compared disease outcomes, treatments, and dose reductions in [...]
Top stories from 2020 for kidney cancer
Dr Sumanta (Monty) Pal, Clinical Professor and Co-Director of the [...]
